A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil^® in Healthy Volunteers Aged 15–35 Years

<b>Background/Objectives:</b> Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies. Although licensed HPV vaccines are highly effective, access remains limited in many low- and middle-income countries du...

Cijeli opis

Bibliografski detalji

Glavni autori:	Erfan Pakatchian, Minoo Mohraz, Mohammad Taghavian, Babak Javadimehr, Hajar Mohammadi Barzelighi, Majid Teymoori-Rad, Mehrdad Ghodsi, Zahra Naderi Saffar
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2026-06-01
Serija:	Vaccines
Teme:	human papillomavirus HPV vaccine quadrivalent HPV vaccine Gardisun Gardasil immunogenicity
Online pristup:	https://www.mdpi.com/2076-393X/14/6/540
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!